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Abstract 
 
Breast cancer is commonly found in women than in men and has been a serious issue for last two 
decades. High level of Hsp90 alpha expression has been documented in many breast cancer cells. 
Hsp90 alpha is dimeric protein with a molecular mass of 90 kDa, well conserved molecular 
chaperone and plays a key role in signal transduction pathways in cancer cells. Inhibition of 
Hsp90 alpha has been shown to be a common therapeutic approach by many reports. For proper 
chaperoning activity, Hsp90 alpha requires a host of other co-chaperones in proper functioning. 
Disrupting the interaction between Hsp90 alpha and co-chaperone will impair its chaperoning 
function and thus inhibit cancer.  
 
In the present investigation, protein-protein interaction studies were done between Hsp90 alpha, 
its co-chaperones and client proteins. Results showed that complex formation is important for 
stabilization and maturation of client proteins. Hsp organizing protein also known as HOP brings 
together Hsp90 alpha and Hsp70 and therefore, inhibiting Hsp90 alpha and HOP interaction may 
lead to the disruption of Hsp90 alpha-Hsp70 complex formation and thus destabilize and degrade 
the client proteins including p53. In order to inhibit Hsp90 alpha and HOP interaction, ten 
numbers of peptides have been designed considering those residues involved in the interaction 
between Hsp90 alpha and HOP using computational methods. In-silico docking method Hex 6.1 
was used to assess the binding energy between peptides and Hsp90 alpha. Based on the energy 
values we selected the peptide with highest negative energy that was the indicative of most stable 
interaction. As peptides commonly form aggregates, amyloidogenic properties of the selected 
peptide were predicted and the peptide was accordingly modified. When the modified peptide 
was interacted with Hsp90 alpha, docking results showed peptide INSAYKLKYARG binds with 
Hsp90 alpha with highest negative free energy of -861.81kcal/mole. The docking of the complex 
with HOP showed less affinity than Hsp90 alpha alone showing the conformational changes 
upon inhibition. 
 
Keywords: Hsp90 alpha, Breast cancer, HOP, Docking, peptide designing 
v 
 
Table of Contents 
 
Acknowledgement ........................................................................................................................ iii 
Abstract ......................................................................................................................................... iv 
Table of Contents…………………………..…………………………………………………….v 
List of Figures………………………………………………………………………………….viii 
List of Tables……………………………………………………………………………………..x 
Abbreviations ............................................................................................................................... xi 
1. INTRODUCTION ..................................................................................................................... 1 
1.1Introduction ............................................................................................................................ 2 
1.1.1 Hsp90 alpha and Breast cancer ....................................................................................... 2 
1.1.2 Computational approaches ............................................................................................. 4 
1.2 Objective: .............................................................................................................................. 5 
2. LITERATURE REVIEW ........................................................................................................ 6 
2.1 Hsp90 alpha (molecular chaperones) .................................................................................... 7 
2.2 Structural organization of Hsp90 alpha ................................................................................. 8 
2.3 Breast cancer and over expression of Hsp90 alpha ............................................................... 8 
2.4 Hsp90 and its client p53 ...................................................................................................... 10 
2.5 Hsp90 alpha inhibitors ........................................................................................................ 11 
 
vi 
 
3. MATERIALS AND METHODS ........................................................................................... 15 
3.1 Database,Software’s and tools used .................................................................................... 16 
3.1.1 NCBI ............................................................................................................................. 16 
3.1.2PDB ............................................................................................................................... 16 
3.1.3 PHYRE ......................................................................................................................... 17 
3.1.4 UCSF CHIMERA ......................................................................................................... 17 
3.1.5 HEX .............................................................................................................................. 17 
3.1.6 PEP-FOLD ................................................................................................................... 18 
3.1.7 PEPTIDE PROPERTY CALCULATOR ..................................................................... 18 
3.1.8 FOLDAMYLOID ......................................................................................................... 18 
3.1.9 LIGPLOT+ .................................................................................................................... 19 
3.2 Protocol ............................................................................................................................... 19 
3.2.1 Interaction between Hsp90 alpha, co-chaperones and client proteins .......................... 19 
3.2.2 Hsp90 alpha peptide Inhibitors ..................................................................................... 20 
3.2.3 Studying the effect of inhibition ................................................................................... 21 
3.3 Methodology ....................................................................................................................... 22 
3.3.1 Hsp90 alpha amino acid sequence ................................................................................ 22 
3.3.2 Homology modeling of Hsp90 alpha using PHYRE2 .................................................. 22 
3.3.3 Retrieval of 3D structure of p53, Hsp70, Hsp40 and HOP from PDB ......................... 23 
3.3.4 Energy minimization .................................................................................................... 23 
vii 
 
3.3.5 Design of peptides ........................................................................................................ 24 
3.3.6 Peptide property calculation ......................................................................................... 24 
3.3.7 Amyloid prediction by FOLDAMYLOID ................................................................... 25 
3.3.8 Docking by HEX 6.1 .................................................................................................... 26 
4. RESULTS AND DISCUSSION ............................................................................................. 27 
4.1 Modeled structure of Hsp90 alpha ...................................................................................... 28 
   4.2 3D Structure of p53,HOP,Hsp70 and Hsp40……………………………………………....29 
4.3 Study of protein-protein interactions .................................................................................. 30 
4.4  Dimplot Analysis (for protein-protein interactions) .......................................................... 31 
4.5 Design of peptides ............................................................................................................... 35 
4.6 Hex 6.1 docking results (protein – protein/peptide) ............................................................ 37 
4.7 Effect of inhibition on binding affinity of Hsp90 alpha, HOP and p53 .............................. 44 
4.8 Discussion ........................................................................................................................... 46 
5. CONCLUSION AND FUTURE PERSPECTIVES ............................................................. 48 
5.1 Conclusions ......................................................................................................................... 49 
5.2 Future perspectives .............................................................................................................. 49 
6. REFERENCES ........................................................................................................................ 51 
  
 
viii 
 
List of Figures 
Figure 1: (a) Domain structure of human Hsp90 alpha showing domain boundaries (b) Ribbon 
diagram of the X-ray crystal structure of dimeric yeast Hsp82, from the complex with Sba1 
(adapted from ref 19) ...................................................................................................................... 9 
Figure 2: Crystallographic structure of Hsp90 alpha N-terminal domain bound to Geldanamycin 
(PDB ID 1YET) ............................................................................................................................ 12 
Figure 3: Chemical structure of the naturally occurring Hsp90 alpha inhibitors (adapted from ref 
27) ................................................................................................................................................. 13 
Figure 4:  Retrieval of amino acid sequences from NCBI ............................................................ 22 
Figure 5:  Submission of amino acids in PHYRE2 ...................................................................... 23 
Figure 6: Energy minimization parameters .................................................................................. 24 
Figure 7:  3D structure of Hsp90 alpha C-terminal domain after energy minimization ............... 28 
Figure 8:  3D structure of wild p53 (A), mutant p53 (B), Hop(C) Hsp70(D) and Hsp40(E) Hsp90 
after energy minimization……………………………………………………………………….29 
Figure 9:  3D structure of Hsp90 HOP complex…………………………………………………31 
Figure 10 A and B : The dimplot analysis of Hsp90 alpha with mutant p53 .…..………………32 
Figure 11 A and B:  The dimplot analysis of Hsp90 alpha with co-chaperone HOP ……………33 
Figure 12:  3D structure of Hsp90 peptide inhibitor complex…………………………………...39 
Figure 13 A and B:  The dimplot analysis of Hsp90 alpha peptide inhibitor complex………… 40 
ix 
 
Figure 14:  (A) Amyloidogenicity prediction of designed peptide INSAYKFKYARG showing 
regions of Amyloidogenic in blue and (B) Amyloidogenicity prediction of modified peptide 
INSAYKLKYARG showing no regions of Amyloidogenic ……………………………………41 
Figure 15: 3D structure of the peptide inhibitor showing highest affinity. .................................. 45 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Tables 
 
Table 1: Interaction of Hsp90 alpha with wild and mutant type p53 ........................................... 30 
Table 2:  Interaction of Hsp90 alpha and co-chaperones .............................................................. 30 
Table 3:  Interaction of multichaperone complex Hsp90 alpha with wild and mutant p53. ......... 31 
Table 4: The residues involved in binding of Hsp90 alpha-Mutant type p53 generated and the 
distance measured by Dimplot ...................................................................................................... 32 
Table 5: The residues involved in binding of Hsp90 alpha- HOP generated and the distance….33 
measured by Dimplot .................................................................................................................... 34 
Table 6: List and structure of designed peptides .......................................................................... 37 
Table 7: Properties of the designed peptides ................................................................................ 38 
Table 8: Docking calculation between Hsp90 alpha and the designed peptides .......................... 41 
Table 9: List and structure of modified peptides .......................................................................... 42 
Table 10: Properties of the modified peptides .............................................................................. 43 
Table 11: Docking calculation between Hsp90 alpha and the modified peptides ........................ 43 
Table 12: Residues of designed peptides interacting with Hsp90 alpha as predicted by Dimplot 
analysis…………………………………………………………………………………………...44 
Table 13: Docking calculation between Hsp90 alpha, HOP and mutant p53 after Hsp90 alpha 
inhibition ....................................................................................................................................... 45 
 
 
 
 
xi 
 
Abbreviations 
 
Hsps                                         Heat Shock Proteins 
HOP                                         Hsps organizing protein 
Asp                                          Aspartic acid 
Thr                                           Threonine 
Phe                                           Phenylalanine 
Lys                                           Lysine 
Gln                                           Glutamine 
His                                            Histidine 
Arg                                           Arginine 
Asn                                           Asparagine 
Ser                                            Serine 
Leu                                           Leucine 
Ile                                             Isoleucine 
Cys                                           Cysteine 
Pro                                            Proline 
Met                                           Methionine 
Val                                           Valine 
Trp                                           Tryptophan 
Glu                                           Glutamic acid 
Tyr                                           Tyrosine 
Gly                                           Glycine 
Ala                                           Alanine 
 1 
 
   
   
  
CHAPTER 1 
 
                  INTRODUCTION 
 
 
 
 
 2 
 
1.1 Introduction 
  
Cancer is one of the most common diseases in the developed world and 1 in 4 deaths are due to 
cancer (Siegel et al., 2012). Lung cancer is most common in men and breast cancer is most 
common in women (Bray et al., 2013 ).There are over 100 different forms of cancer. Normal 
body cells grow, divide and die in a controlled and co-ordinated manner and these cells are in 
communication with each other involving delicate and complex signaling and communication 
pathways. Sometimes there is disturbance in the controlled and coordinated growth due to 
various external factors and genetic mutation and such loss of control can cause cancer. Before 
cancer formation, the cells undergo tumor formation. These tumors are classified into two types, 
benign and malignant. It is the malignant tumor that results in cancer and metastasis. Cancer may 
be caused by several reasons primarily due to mutations in DNA leading to disturbances in 
regulatory pathways and cell cycle. Although there are many types of cancer, they all are 
generates because of uncontrolled growth of abnormal cells. 
 
1.1.1   Hsp90 alpha and Breast cancer  
 
Hsps (Heat Shock Proteins) are highly conserved ubiquitous proteins among species which are 
involved in maintaining appropriate folding and conformation of other protein and thus known as 
molecular chaperones. Hsp90 alpha is one of the groups of the molecular chaperones responsible 
for protein folding and quality control in cellular environment. It comprises 1-2% of total 
proteins under non stress conditions. It regulates the stability and activation of more than 200 
client proteins (Calderwood and Gong, 2012). Recent studies indicate that Hsp90 alpha is a 
major interaction node, regulating a diverse set of cellular functions. 
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Hsp90 alpha is involved in the maturation and stabilization of a wide range of oncogenic client 
proteins (Beliakoff and Whitesell, 2004). Cancer cells are heavily dependent on proper Hsp90 
alpha functioning. Many of the client proteins which turn oncogenic are either mutated e.g. p53 
or over expressed or both (Ciocca et al., 1992). Many harsh environmental conditions are found 
in tumors such as hypoxia, low pH and bad nutritional status making client proteins heavily 
dependent on Hsp90 alpha. The expression of Hsp90 alpha is high compared to normal cells 
indicating that its inhibition would help check the proliferation of cancer cells, followed by 
proteasomal degradation offering a combinatorial impact. This approach also reduces the 
chances to develop resistance by cancer cells. As Hsp90 alpha is associated with a plethora of 
pathways viz, signal transduction, cell cycle, transcriptional regulation and many others it is a 
good target for many diseases especially cancer(Conroy and Latchman, 1996). 
Cancer is the main cause of death found globally, around 7.6 million deaths (around 13% of all 
deaths) in 2008, with an estimated 13.1 million deaths in 2030.  Out of which breast cancer 
covers 22.9% of all cancers in females. 13.7% of breast cancer deaths were recorded in 2008 in 
women all over the world (Soerjomataram et al., 2012) . The incidence of breast cancer in India 
is increasing day by day and is quickly becoming the number one cancer in females. The 
significance of the situation is obvious after running through present data from Indian Council of 
Medical Research (ICMR).   
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1.1.2  Computational approaches 
 
Application of computational approaches to drug designing is becoming widespread since there 
is a plethora of public databases and free software.  Main application of bioinformatics and 
chemoinformatics include the rapid and economical initial screening and lead identification of 
drug like compounds for further developments. Without these tools individual experimental 
screening would have been a costly affair. These have resulted in speeding of drug discovery 
process. Rational or knowledge based drug design facilitates and speeds up the drug designing 
processes that involves various method of identifying novel compounds. One advanced method 
is the docking of the drug molecule or ligand or inhibitor with the target also known as structure 
based virtual screening. Another form of virtual screening is the ligand based virtual screening 
where knowledge of known ligand is used for screening. In docking two molecules bind to each 
other in 3D space. There are three types of docking viz, rigid, flexible, and semi-flexible 
docking. In addition, regression based or knowledge based scoring functions can be useful to 
compute the free energy of ligand binding (Oprea and Matter, 2004). Various tools, software’s 
and servers are available for docking calculations. Different databases are available where one 
can find the 3D structures of macromolecule and ligand which are extracted from NMR and X-
RAY co-ordinates .Thus before doing the actual experimental work one can easily do a virtual 
study of his problem and after coming to a viable solution start the experiment which will reduce 
time and money. 
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1.2.1 Objective 
 
1. To Design small peptides as the Hsp90 alpha inhibitor based on the residues involved in 
the interaction between Hsp90 alpha and HOP. 
2. To estimate docking energies between designed peptides and Hsp90 alpha and the multi-
chaperone complex. 
3. To identify the best peptide based on the binding affinity. 
4. Analysis of docking result with LIGPLOT+ to understand type of interaction. 
5. To compare the binding affinity of the interaction between Hsp90, p53 and HOP before 
and after inhibition. 
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LITERATURE REVIEW 
 
 
2.1 Hsp90 alpha (molecular chaperones) and cancer  
 
Heat-shock protein 90 (Hsp90 alpha) is a molecular chaperone (Csermely et al., 1998) that 
participates in the quality control of protein folding. Hsp90 alpha functions by recruiting many 
co-chaperones viz, Cdc37, Hop, p23, Hsp70 and Hsp40 (Li et al., 2012a). The complex 
formation is an energy requiring step and involves sequential ATPase cycles (Richter et al., 
2004). Client proteins of Hsp90 alpha are several kinases viz, AKT, B-Raf mutant, MET and 
CDK4; Transcriptional factors HIF-1A, ERA-receptors p53 mutant regulating cell proliferation 
and survival and chimeric fusion proteins (Theodoraki and Caplan, 2012). Cancer cells are 
stressed cells and heavily depend on Hsp90 alpha chaperoning and thus show higher levels of 
expression of Hsp90 alpha, therefore Hsp90 alpha has emerged as a target for cancer therapy 
(Hong et al., 2013). Many drugs targeting ATP binding domain have been developed and are in 
clinical trials. Geldanamycin a prototype example of ansanamycins antibiotic showed exciting 
results disrupting multiple pathways but was toxic to normal cells and hence could not enter 
clinical trials (Fukuyo et al., 2010). Analogoues of geldanamycin 17-AAG and 17-DMAG were 
designed which was non toxic to human cells (Li et al., 2012b). Hsp90 alpha inhibitors found in 
literatures have mostly been discovered by structure based virtual screening, generating 
derivatives from already existing inhibitors or finding new scaffolds by HTS (Li et al., 2009). 
Recently Shepherdin, a novel anticancer agent was designed based on the interaction between 
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Hsp90 alpha and surviving (Plescia et al., 2005). Survivin is a mitotic regulator and antiapoptotic 
protein involved in many pathways (Duffy et al., 2007). The structure of shepherdin was based 
on modelled interface between Hsp90 alpha and survivin.  
 
2.2   Structural organization of Hsp90 alpha 
 
It contains 3 domains: an N-terminal approximately 25-KDa, a middle domain approximately 
35KDa and C-terminal domain approximately 10KDa. ATP binding site is located in N-terminal 
domain of Hsp90 alpha (Beliakoff and Whitesell, 2004). Hsp90 alpha has two isomers alpha and 
beta encoded by two distinct genes, share approximately 81% sequence homology. While Hsp90 
alpha beta is constitutively expressed at high abundance in most tissues, Hsp90 alpha is typically 
inducible in response to various cellular stress conditions (Cooper et al., 2011).  The folding of 
the client protein mainly occurs in the middle domain. Hsp90  alpha  function in a dimer form. It 
dimerizes through the C-terminal domain, besides this domain also interacts with the HOP 
(Csermely et al., 1998). HOP is an Hsp organizing protein .It helps in proper chaperoning of 
Hsp90 alpha. HOP through its tpr2a domain binds to the C-terminal of Hsp90 alpha and through 
its tpr1 domain to the N-terminal of Hsp70. Client protein comes to Hsp90 alpha via Hsp70 and 
both are joined by HOP(Onuoha et al., 2008; Pimienta et al., 2011; Southworth and Agard, 
2011).  
2.3   Breast cancer and over expression of Hsp90 alpha 
 
In breast cancer, a number of client proteins interact with Hsp90 alpha. Some of the client 
proteins are estrogen receptors, p53 protein, hypoxia-induced transcription factor HIF-1alpha, 
protein kinase Akt, Raf-1 MAP kinase and a number  of receptor tyrosine kinases, such as erbB2 
 9 
 
(Beliakoff and Whitesell, 2004; Cho et al., 2006; Sreedhar et al., 2004). It has long been 
appreciated that tumor cells are “stressed” cells capable of coping with unfavorable 
environments via a generalized up-regulation of their stress response machinery(Kastan, 2007). 
                        
 
Figure 1: (a) Domain structure of human Hsp90 alpha showing domain boundaries (b) Ribbon diagram 
of the X-ray crystal structure of dimeric yeast Hsp82, from the complex with Sba1 (adapted from ref 
(Park et al., 2011b)). 
 
This is largely centered on the expression and function of the molecular chaperone Hsp90 alpha, 
which is highly expressed in breast cancer and has provided an attractive target for therapeutic 
intervention in cancer (Beliakoff and Whitesell, 2004) . High Hsp90 alpha expression level has 
been detected in invasive breast carcinomas   and is associated with reduced survival in breast 
cancer (Pick et al., 2007). 
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 2.4   Hsp90 and its client p53 
 
p53, also known as the “guardian of genome” is important client protein of Hsp90 and also the 
first tumor suppressor gene was discovered. Structurally it consists of four domains each with a 
different function and a total of 393 amino acid (Park et al., 2011b). The expression of p53 is low 
in normal cells and functions to inhibit and eliminate proliferation of normal cells (Lane and 
Hupp, 2003). Mouse double minute 2 (MDM2) is important regulatory protein of p53 and 
responsible for its degradation via proteosomal degradation pathway by binding to the C-
terminus of p53 (Park et al., 2011b; Wang and Jiang, 2012). In cancer p53 is inactivated by 
multiple mechanisms. Mutant p53 has been found in number of breast cancer cases. Majority of 
mutation is located in the DNA-binding domain(Feki and Irminger-Finger, 2004). Experiments 
have shown the crucial role of Hsp90 in stabilizing mutant p53. Hsp90 blocks the E3 ubiquitin 
ligase activity of Mdm2 thus preventing the degradation of mutant p53 (Brooks and Gu, 2003; 
Michael and Oren, 2003). 
Structural analysis of interaction between Hsp90 and p53 has been done by many researchers. 
NMR studies showed that the core domain of p53 is bound to Hsp90 in unstructured fashion. 
Various domains of Hsp90 interact with p53 with most of the association with middle domain. 
Besides middle domain it also binds loosely to N-terminal and C-terminal domain (Hagn et al., 
2011). Molten globule like state of p53 has been reported to form upon interaction with middle 
domain of Hsp90 (Park et al., 2011a). In contrast, it has also been reported there is no structural 
changes and p53 binds natively to Hsp90 based on charge and shape (Hagn et al., 2011). 
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2.5   Hsp90 alpha inhibitors  
 
Hsp90 alpha inhibitors are categorized in four classes based on their mechanism: 
1) Blocking of ATP binding site 
2) Disruption of co-chaperone/Hsp90 alpha interaction 
3) Antagonism of client/Hsp90 alpha associations 
4) Interference with post-translational modifications of Hsp90 alpha 
 
2.5.1   Hsp90 alpha inhibitors targeting the ATP binding site 
 
Benzoquinone ansamycins, represented by Geldanamycin (Figure 3) were the first class of 
natural Hsp90 alpha inhibitors to be discovered and substantially studied (Fukuyo et al., 2010). 
Geldanamycin, a natural occurring antibiotic, was originally isolated from Streptomyces 
hygroscopicusas early as 1970s. But GA exhibited high hepatotoxicity observed in animal 
models. Therefore GA derivatives like 17AAG,17 DMAG were synthesized and tested but still 
suffer from problems like low water-solubility, instability in solution, and low oral 
bioavailability  may become the obstacle to further clinical application (Gartner et al., 2012). To 
avoid the problems of natural inhibitors synthetic small molecule and peptides have been 
designed with high specificity for Hsp90 alpha (Modi et al., 2011).It has been possible due to the 
crystal structure of Hsp90 alpha and powerful computational methods of screening called virtual 
screening. Compounds were designed based on purine and pyrazole scaffold mimicking the 
shape of natural nucleotide (Caldas-Lopes et al., 2009). Short peptide derivatives composed of 
three core amino acids Phe-D-Trp-Leu, were synthesized and reported to inhibit ATP (Orosz et 
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al., 2006) . Recently a novel peptide called shepherdin was designed to inhibit the interaction 
between Hsp90 alpha and survivin(Plescia et al., 2005).  
                                   
2.5.2   Hsp90 alpha inhibitors targeting co-chaperone/Hsp90 alpha interactions 
 
For the proper functioning of Hsp90 alpha, a series of co-chaperones are required. Binding and 
leaving of the co-chaperones at various stages provide regulatory control to the chaperoning 
process of Hsp90 alpha (Neckers, 2002).Therefore, blocking the chaperone cycle at these stages 
by targeting different co-chaperone/Hsp90 alpha interactions is likely to achieve similar results 
with the direct inhibition of Hsp90 alpha (Gray et al., 2008). Various co-chaperones targeted so 
far are cdc37/Hsp90 alpha, Hsp70/Hsp90 alpha, HOP/Hsp90 alpha and Aha1/Hsp90 alpha 
(Cortajarena et al., 2008; Holmes et al., 2008; Onuoha et al., 2008; Smith et al., 2009). 
                         
Figure 2: Crystallographic structure of Hsp90 alpha N-terminal domain bound to Geldanamycin (PDB ID 
1YET). 
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Figure 3: Chemical structure of the naturally occurring Hsp90 alpha inhibitors (adapted from ref (Li et 
al., 2009)). 
 
2.5.3  Hsp90 alpha inhibitors targeting client/Hsp90 alpha associations 
 
By targeting the client/Hsp90 alpha interactions  selectivity might be possible , but not much is 
known for the structural basis of these interactions (Pearl et al., 2008). A peptidomimetic 
compound called as shepherdin was designed to disrupt the Hsp90 alpha/survivin interaction 
(Plescia et al., 2005) . However, shepherdin also interacted with the ATP pocket of Hsp90 alpha, 
and affects a range of Hsp90 alpha clients in addition to surviving (Pearl et al., 2008) .  
2.5.4  Post-translational modifications of Hsp90 alpha 
 
Out of the Post-translational modifications, studied so far S-nitrosylation, hyperphosphorylation 
and reversible hyperphosphorylation, have been  implicated in regulating chaperone function of 
Hsp90 alpha (L, 2007). Indirect disturbance of the activity of Hsp90 alpha through post-
translational modifications may open up new avenues for drug discovery (Wandinger et al., 
 14 
 
2006). Some of the post translational modifications studied so far are Hsp90 alpha 
hyperacetylation(HDAC’S), Hsp90 alpha thiol oxidation and Hsp90 alpha phosphorylation 
(Chen et al., 2008; Kovacs et al., 2005; Yang et al., 2008) 
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MATERIALS AND METHODS 
 
3.1 Database, Software’s and Tools used 
 
3.1.1 NCBI    
 
NCBI (www.ncbi.nlm.nih.gov) stands for NATIONAL CENTRE FOR BIOTECHNOLOGY 
INFORMATION is part of the United States NATIONAL LIBRARY OF MEDICINE (NLM) a 
branch of the NATIONAL INSTITUTE OF HEALTH (NIH) and it is located in Bethesda, 
Maryland. NCBI has many databases cross linked to each other. Genome databases are in 
GenBank, biomedical research articles are in PubMed Central and PubMed both free access, and 
articles relevant to biotechnology. Entrez search engine provides searching through various 
databases. 
 
3.1.2 PDB  
 
RCSB PROTEIN DATA BANK (www.rcsb.org) is an information portal to biological 
macromolecule structure. It is a repository of 3D structural data of biological molecules such as 
nucleic acids and proteins. The datas are obtained experimentally from X-RAY crystallography 
studies and NMR studies by researchers and submitted from around the world. I t can easily be 
accessed from internet from its website. As of Tuesday November 27 2012 there are 86487 
structures 
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3.1.3  PHYRE 
 
PHYRE stands for Protein Homology/analogY Recognition Engine is a server for protein 
structure prediction using homology modeling techniques and is free for academic users. It is 
widely used with approximately 1000 citations and 4150 submissions per day is user friendly and 
have a simple interface to results (Kelley and Sternberg, 2009).  
3.1.4  UCSF CHIMERA 
 
Chimera is program for visualization and structural analysis of molecular structures and related 
data including including density maps, sequence alignments supramolecular assemblies, docking 
results, trajectories, energy minimization, conformational ensembles and many other tasks. 
Publication quality Images and movies can also be created in it. It has extensive documentation 
and is available free for academic users (Pettersen et al., 2004). 
 
3.1.5  HEX 
 
Hex is an interactive program for calculating and displaying feasible docking modes. It is an 
Interactive Molecular graphics program developed by Dave Ritchie for estimating docking 
calculations and displaying docking modes of pairs of protein and ligand molecules. HEX is used 
as the docking tool which calculates intermolecular “energies” by adding up all intermolecular 
interactions (e.g. van der Waals, electrostatic) that occur between a ligand and protein target. It 
can perform protein-protein docking taking receptor as rigid. Hex docking calculation each 
molecule is modeled using 3D expansions of real orthogonal spherical polar basis function to 
encode both surface shape and electrostatic charge and potential distributions. Typical docking 
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requires loading a receptor which is treated as rigid and ligand as movable. First it performs a 
spherical polar fourier transform based on 3D structure, then there is fast fourier transform steric 
scan and final search followed by a molecular mechanics refinements(Ritchie, 2008). 
3.1.6  PEP-FOLD 
 
PEP-FOLD is a program for de-novo structure prediction of peptides. The word de-novo means 
starting from the beginning .Rational peptide design and large scale prediction of peptide 
structure from sequence is a challenge .PEP-FOLD is a program for de-novo modeling of 3D 
conformation of peptides between 9 and 25 amino acids. It builds structure only from the 
sequence information based on the concepts of structural alphabets (SA) .It is a two step process 
prediction of a limited set of SA letters at each position from sequence and then assembling of 
the prototype fragments associated with each SA letters using a revised version of greedy 
algorithm and a generic protein coarse-grained force field (J. Maupetit et al., 2007; Maupetit et 
al., 2009; Maupetit et al., 2007). 
3.1.7 PEPTIDE PROPERTY CALCULATOR 
 
Various properties of the peptide can be calculated from INNOVAGEN’S 
(www.innovagen.com) peptide property calculator. The properties calculated are molecular 
weight, net charge, isoelectric point and solubility. 
3.1.8 FOLDAMYLOID 
 
Amyloidogenic regions in peptides are very important because such regions are responsible for 
amyloid formation and aggregation which might cause it to become non-functional and harmful. 
It has been seen that only small fragment are required for amyloidogenisis and the fragments are 
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able to form fibrils even without whole protein. Most of the fragments have an elevated content 
of hydrophobic amino acids residues called type1 and regions rich in ASN and GLN called type 
2. FOLDAMYLOID predicts amyloidogenisis on the basis of sequence in fasta format. This 
program is based on hydrogen bond statistics and based on using expected characteristics scales  
either expected packing density or the probability of formation of hydrogen bonds(Garbuzynskiy 
et al., 2010). 
3.1.9 LIGPLOT+ 
 
LIGPLOT+ software is a program for plotting 2D protein-ligand (LIGPLOT) and protein-protein 
(DIMPLOT) interaction diagram and is free for academic users. It is an improved version of the 
earlier LIGPLOT. Hydrogen bonds and hydrophobic interactions are the two major interactions 
which are shown by dashed lines and arc with spokes respectively. It has several addition of new 
features viz, Superposition of related diagram, Improved DIMPLOT program and Links to 
PyMOL and RasMol (Laskowski 2011). 
 
3.2 Protocol  
 
      3.2.1 Interaction between Hsp90 alpha, co-chaperones and client proteins 
 
Retrieval of amino acid sequences of Hsp90 alpha protein from NCBI 
                                                                                                                       
3D structure modeling of  Hsp90 alpha Protein using PHYRE server. 
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3-D structure of p53, Hsp70, Hsp40, HOP and client proteins retrieved from PDB (Protein Data 
bank). 
                     
Energy minimization of all 3D structure of proteins done by UCSF  Chimera. 
 
Docking of individual protein and  protein complex respectively done by Hex 6.1. 
 
Retrieval of the residues involve at the binding site by Dimplot analysis. 
 
 
 
 3.2.2   Design and assessing the binding efficiency of Hsp90 alpha peptide Inhibitors 
 
Design of peptide inhibitors based on residues involved in Hsp90 alpha HOP interaction 
 
 
De-novo structure modeling of peptides using PEP-FOLD 
 
 
Energy minimization using UCSF chimera 
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Docking of Hsp90 alpha with peptides was done by Hex 6.1 
 
 
 
Analysis of the binding energy obtained from docking. 
 
 
Amyloidogenesis prediction using FOLD-AMYLOID and modification of peptides 
 
 
Docking of the modified peptides using Hex 6.1 
 
 
 
3.2.3 Estimating the effect of peptide inhibition 
 
Retrieval of the protein-peptide complex from HEX 6.1 docking  
 
 
Docking of the complex with HOP and mutant p53 by Hex 6.1 
 
 
Analysis of the total energy values changes before and after inhibition. 
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3.3 Methodology 
 
3.3.1 Hsp90 alpha amino acid sequence 
 
Retrieval of amino acid sequences of Hsp90 alpha protein from NCBI was done by entering 
[HSP90 ALPHA AND “homo sapiens”] in the search option and selecting protein from the 
database option. There were many results of the search but the NCBI Reference Sequence: 
NP_005339.3 was selected and the sequences were retrieved in fasta format Figure.4. 
3.3.2 Homology modeling of Hsp90 alpha using PHYRE2 
 
The retrieved amino acid sequence of Hsp90 alpha in fasta format was pasted in the space 
provided, along with the email id and project title Figure. 5. Result was sent in given email 
within few hours and accessed by going to the link provided.  
 
                                   
Figure 4:  Retrieval of amino acid sequences from NCBI 
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3.3.3 Retrieval of 3D structure of p53, Hsp70, Hsp40 and HOP from PDB 
 
For retrieving the 3D structure of proteins which are available in public databases like PDB go to 
the website of PDB (www.pdb.org) and in the search box type the individual names and very 
judiciously select the proteins. Human wild type p53 - 2OCJ, mutant p53 -2QVQ, HOP - 1ELR, 
Hsp70-3ATU and Hsp40-2QLD were retrieved from protein data bank (PDB). 
3.3.4 Energy minimization  
 
Prior to actual docking the 3D structure of protein was prepared in chimera by removing 
unwanted ions, solvents and ligands and minimizing the structure for high stability. The 
minimize structure functions calls add hydrogen and add charges, standard charges were added 
 
 
                        
Figure 5:  Submission of amino acids in PHYRE2. 
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to standard residues and gasteiger charges were added to non standard residues. The standard 
charges were computed by the AMBER module and missing side chains were replaced by 
dunbrack rotamer library. The energy minimization parameters are shown in Figure 6. 
                  
                       Figure 6: Energy minimization parameters 
 
 
3.3.5 Design of peptides 
 
In silico docking of Hsp90 alpha and HOP was done using Hex. The complex of Hsp90 alpha 
and HOP is required for proper chaperoning activity of Hsp90 alpha. The complex also brings 
other co-chaperones together and facilitates proper presentation of client protein. The key 
residues involved in this interaction was identified using LIGPLOT+ software a program for 
plotting protein-ligand(LIGPLOT) and protein-protein(DIMPLOT) interaction diagram.  After 
docking of the Hsp90 alpha with target HOP, the residues interacting with the active site were 
selected for the design of new sequential peptide .Structure of proposed peptides was modeled 
using Mobyle server at RPRS portal using PEP-FOLD program. PEP-FOLD is a program for de-
novo structure prediction of peptides. Rational peptide design and large scale prediction of 
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peptide structure from sequence is a challenge .PEP-FOLD is a program for de-novo modeling of 
3D conformation of peptides between 9 and 25 amino acids (Maupetit et al., 2009). It builds 
structure only from the sequence information based on the concepts of structural alphabets (SA) 
.It is a two step process prediction of a limited set of SA letters at each position from sequence 
and then assembling of the prototype fragments associated with each SA letters using a revised 
version of greedy algorithm and a generic protein coarse-grained force field. 
3.3.6  Peptide property calculation 
 
For the calculation of peptide properties such as molecular weight, net charge, isoelectric point 
and solubility the single letter code of peptide was entered in the box from N-terminal to C-
terminal without blocking. 
 
3.3.7 Amyloid prediction by FOLDAMYLOID 
 
Since Amyloidogenic regions in peptides are very important because such regions are 
responsible for amyloid formation and aggregation which might cause it to become non-
functional and harmful therefore amyloidogenicity was predicted using FOLDAMYLOID 
program. It has been seen that only small fragment are required for amyloidogenisis and the 
fragments are able to form fibrils even without whole protein. Most of the fragments have 
elevated contents of hydrophobic amino acids residues called type1 and regions rich in ASN and 
GLN called type 2.  FOLDAMYLOID predicts amyloidogenisis on the basis of sequence in fasta 
format. This program is based on hydrogen bond statistics and based on using expected 
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characteristics scales   either expected packing density or the probability of formation of 
hydrogen bonds. 
3.3.8  Molecular Docking by Hex 6.1 software 
 
Hex 6.1 is an Interactive Molecular graphics program developed by Dave Ritchie for estimating 
docking calculations and displaying docking modes of pairs of protein and ligand molecules. 
Hex is used as the docking tool which calculates intermolecular “energies” by adding up all 
intermolecular interactions (e.g. van der Waals, electrostatic) that occur between a ligand and 
protein target. For a typical Hex docking open the Hex window load receptor and ligand 
separately necessary editing can be done many options are provided like change scene, change 
origin etc. Then click the docking control panel select shape +electrostatics because it is close to 
reality keeps other parameters default and run docking, usually it takes 2 to 4 hours to finish. 
After docking completion save the file in .pdb format for future analysis and note down the 
binding energy. 
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RESULTS AND DISCUSSION 
 
4.1  Modeled structure of Hsp90 alpha 
 
The Hsp90 alpha structure was modeled, using the PHYRE2 homology modeling. Homology 
modelling is the most reliable method of structure prediction; other methods are Threading and 
ab-initio modelling. For Homology modelling Template identification is a crucial step, requiring 
sequence identity more than 25%.  The model is shown in Figure 7. The modeled structure 
contains C-terminal domain. The spiral looks in the structures are α- helices and the arrow ones 
are β-sheets. 
                              
Figure 7:  3D structure of Hsp90 alpha C-terminal domain after energy minimization 
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4.2 3D structure of p53, HOP, Hsp70 and Hsp40  
                                         
 
                                           
                                              
Figure 8:  3D structure of wild p53 (A), mutant p53 (B), Hop(C) Hsp70 (D) and Hsp40 (E) Hsp90 after 
energy minimization. 
D 
E 
C 
B A 
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4.3   Study of protein-protein interactions 
 
Protein-protein interaction study was performed with Hsp90 alpha and its co-chaperones Hsp70, 
Hsp40 and HOP along with client protein p53. First Hsp90 alpha alone was interacted with wild 
type and mutant p53, followed by sequential complex preparation and this complex was used to 
interact with wild type and mutant p53. The results of the interaction are tabulated in Table 1 
Table 2 and Table 3 respectively. From the interaction studies it can be inferred that Hsp90 alpha 
binds strongly to HOP(Figure 9) than other co-chaperones and complex formation is important 
for proper chaperoning activity of Hsp90 alpha as complex binds more strongly to client proteins 
than Hsp90 alpha. 
Table 1: Interaction of Hsp90 alpha with wild and mutant type p53 
 
Table 2:  Interaction of Hsp90 alpha and co-chaperones 
 
 
 
Protein Client Protein Docking Energy(Kcal/mol) 
Hsp90 alpha Wild type p53 -647.67 
Hsp90 alpha Mutant type p53 -721.49 
Protein Co-chaperones Docking energy(Kcal/mol) 
Hsp90 alpha HOP -1179.80 
Hsp90 alpha Hsp70 -666.49 
Hsp90 alpha Hsp40 -613.86 
Hsp90 alpha+HOP Hsp70 -656.56 
Hsp90 alpha+HOP+Hsp70 Hsp40 -615.46 
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Table 3:  Interaction of multichaperone complex Hsp90 alpha with  wild and mutant p53. 
 
 
 
                                                 
                                             Figure 9:  3D structure of Hsp90 HOP complex 
                                                                                    
4.4   Dimplot Analysis (for protein-protein interactions) 
 
Protein –protein 2D interaction maps was plotted by using DIMPLOT module of LIGPLOT +.  
Hydrogen bonding and distance between residues is represented by dotted line , arc represent 
Hydrophobic interaction, Hsp90 alpha residues are depicted by maroon color and the pink color 
depict the co-chaperone /client proteins  residues(both Polar and non-polar). 
Complex Client protein Docking energy(Kcal/mol) 
Hsp90 alpha+HOP+Hsp70 
+Hsp40 
Wild type p53 -759.44 
Hsp90 alpha+HOP+Hsp70 
+Hsp40 
Mutant type p53 -926.49 
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                           Figure  10 A and B: The dimplot analysis of Hsp90 alpha with mutant p53 
 
A 
B 
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                       Figure 11 A and B:  The dimplot analysis of Hsp90 alpha with co-chaperone HOP 
B 
A 
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The results of Dimplot analysis are tabulated below 
Table 4: The residues involved in binding of Hsp90 alpha-Mutant type p53 generated and the distance 
measured by Dimplot. 
 
 
 
 
 
Table 5: The residues involved in binding of Hsp90 alpha- HOP generated and the distance measured by 
Dimplot. 
 
 
 
 
 
 
 
 
The hydrophobic residues of Hsp90 alpha involved in the interaction with mutant type p53 are 
Lys581, Ile664, Lys654, Asn655, Pro681, Ser658, Lys657, Asp661, Glu580, Leu579, Ile578, 
Gln682, Arg690, Lys693, Lys615, Ser677, Thr683, Lys582 And Glu679 and the hydrophobic 
residues of mutant type p53 are Ala138, His233, Leu201, Asn200, Ser116, Glu224, Val197, 
Hsp90 alpha residue Mutant p53 residue Distance in angstrom 
Asp577 Gly199 3.33 
Lys660 Gly199 2.74 
Asp680 Cys124 3.03 
Active residues of Hsp90 
alpha 
Residues of HOP 
Hydrophobic Hydrogen bonding 
Asp723 Tyr236 - 
Thr725 Asn233 - 
Ser726 - Tyr248 
Arg727 Arg305 - 
Met728 - Arg305 
Glu730 Ala304,Asn308,Tyr323 - 
Val731 Asp334 - 
Asp732 Lys337,Lys338   Gln341 
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Arg196, Asn235, Glu198, His115, Ser227,Gly226, Val225, Lys120, Ser121, Leu114, Thr140, 
Lys139 and Thr123. The residues involved in hydrogen bonding are put down in Table 4. 
4.5   Design of peptides 
 
Peptides were designed based on the 1ELR, TPR2A domain of Hsp organizing protein and 
Hsp90 alpha interact to form a complex. This complex is required for proper chaperoning 
activity of Hsp90 alpha. The complex also brings other co-chaperones together and facilititate 
proper presentation of client protein like p53 etc. Initially a set of ten  peptides of twelve amino 
acids was designed by Mobyle server taking into consideration all the interacting residues of the 
HOP and by random altering of the desired location of amino acid residues within the peptide 
(Table 6). Table 7 lists the molecular weight, solubility, and other properties of modeled 
peptides. For de-novo structure prediction of the designed peptide single letter amino acid 
sequence was entered in fasta format in the PEP-FOLD program. List and structure of designed 
peptide are given in Table 6. 
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Table 6: List and structure of designed peptides 
S.no Peptide Structure 
1 KYFKYAGRIANS 
 
2 KYAGRIANSYFK 
 
3 GRIANSYFKKYA 
 
4 ANSKYFKYAGRI 
 
5 KAYARIGNSYFK 
 
6 AGRIANSKYFKY 
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4.6 Hex 6.1 docking results (protein – protein/peptide) 
 
Various energies of the designed peptide after docking with Hsp90 alpha are listed in Table 8. 
Comparative analysis of peptides interprets that new peptide (INSAYKFKYARG) as shown in 
Table 8; possess high binding affinity. However this peptide suffered from amyloidogenicity as 
predicted by FOLD AMYLOID program (Figure 14 (A)). Amyloidogenicity prediction of 
designed peptide INSAYKFKYARG showing regions of Amyloidogenic in regions 5-9.The 
region which shows amyloidogenicity is YKFKY. 
7 INSAYKFKYARG 
 
8 KAYAAAGNSYFK 
 
9 KAYARIGNSGGG 
 
10 RKFSAAIGYNKY 
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Table 7: Properties of the designed peptides 
 
 
 
 
 
 
 
 
 
 
To remove amyloidogenicity the “F” residue was substituted with M, A, L, E, K respectively 
because these residues have higher affinity to be in helix confirmation. Amyloidogenicity 
prediction of modified peptide INSAYKLKYARG showed no regions of Amyloidogenic (Figure 
14(B)) .The modified peptides again went through the process mentioned above. Table 9 shows 
the list, Table 10 properties of the modified peptides and Table 11 binding energy with Hsp90 
alpha. The structure of Hsp90 alpha and inhibitor peptide complex is given in Figure 10. Peptide 
INSAYKLKYARG (Figure 11) showed to bind with high affinity.  
 
Peptide property calculator showed that INSAYKFKYARG peptide having isoelectric point of 
10.33 with a net charge of 3 at neutral pH. In silico solubility of the peptide in pure water was 
checked and was found to be good. Solubility is calculated based on the iso-electric point, 
     Peptide Molecular 
weight 
Isoelectric point Net charge 
at pH=7 
Solubility 
KYFKYAGRIANS 1417.63g/mol 10.33 3 good 
KYAGRIANSYFK 1417.63g/mol 10.33 3 good 
GRIANSYFKKYA 1417.63g/mol 10.33 3 good 
ANSKYFKYAGRI 1417.63g/mol 10.33 3 good 
KAYARIGNSYFK 1417.63g/mol 10.33 3 good 
AGRIANSKYFKY 1417.63g/mol 10.33 3 good 
INSAYKFKYARG 1417.63g/mol 10.33 3 good 
KAYAAAGNSYFK 1290.44g/mol 9.94 2 poor 
KAYARIGNSGGG 1150.26g/mol 10.4 2 good 
RKFSAAIGYNKY 1417.63g/mol 10.33 3 good 
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number of charged residues and the length of peptide. Residues of designed peptide involved in 
binding with Hsp90 alpha was plotted using LIGPLOT+. 2D Diagram of the interaction is shown 
in Figure 13 and the results are tabulated in Table 12.According to the results Glu730 and 
Val731 are the two key residues participating in hydrogen bonding and stabilizing the 
interaction. Various other residues involved in hydrophobic interactions are also tabulated in 
Table 12. 
 
 
                              
                           Figure 12:  3D structure of Hsp90 peptide inhibitor complex 
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Figure 13 A and B:  The dimplot analysis of Hsp90 alpha peptide inhibitor complex. 
A 
B 
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Figure 14:  (A) Amyloidogenicity prediction of designed peptide INSAYKFKYARG showing regions of 
Amyloidogenic in blue and (B) Amyloidogenicity prediction of modified peptide 
INSAYKLKYARG showing no regions of Amyloidogenic 
 
Table 8: Docking calculation between Hsp90 alpha and the designed peptides 
 
 
 
 
 
                                     
                          
 
 
 
 
 
Protein Peptide Energy(kcal/mol) 
 KYFKYAGRIANS -824.22 
 KYAGRIANSYFK -823.04 
 GRIANSYFKKYA -746.73 
 ANSKYFKYAGRI -819.08 
Hsp90 alpha KRIGAYFKYANS -678.81 
 AGRIANSKYFKY -815.99 
 INSAYKFKYARG -850.57 
 KAYAAAGNSYFK -716.06 
 KAYARIGNSGGG -736.48 
 RKFSAAIGYNKY -657.09 
A B 
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                                               Table 9: List and structure of modified peptides 
 
 
 
 
  
S.no Peptide Structure 
1 INSAYKMKYARG 
 
 
2 INSAYKAKYARG 
 
3 INSAYKLKYARG 
 
4 INSAYKEKYARG 
 
5 INSAYKKKYARG 
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Table 10: Properties of the modified peptides 
 
 
Table 11: Docking calculation between Hsp90 alpha and the modified peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide Molecular 
weight 
Isoelectric point Net charge 
at pH=7 
Solubility 
INSAYKMKYARG 1410.65g/mol 10.33 3 good 
INSAYKAKYARG 1341.53g/mol 10.33 3 good 
INSAYKLKYARG 1383.62g/mol 10.33 3 good 
INSAYKEKYARG 1399.57g/mol 9.94 2 good 
INSAYKKKYARG 1398.63g/mol 10.54 2 good 
Protein      Peptide     Energy(kcal/mol) 
 INSAYKMKYARG -776.29 
 INSAYKAKYARG -770.81 
Hsp90 alpha INSAYKLKYARG -871.81 
 INSAYKEKYARG -659.58 
 INSAYKKKYARG -835.52 
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Table 12 Residues of designed peptides interacting with Hsp90 alpha as predicted by Dimplot analysis 
 
 
 
 
 
 
 
 
 
 
 
 
4.7   Effect of inhibition on binding affinity of Hsp90 alpha, HOP and p53  
 
Docking studies showed good affinity between Hsp90 alpha, HOP and p53 .HOP is very 
important for organization of Hsp90 alpha and Hsp70 for proper presentation of client proteins 
viz, p53 etc. Results showed that the affinity for mutant p53 is more than wild type p53, hence it 
can be inferred that Hsp90 alpha is the main culprit which protects mutant p53 from being 
degraded. To study the effect of inhibition Hsp90 alpha/peptide inhibitor complex was docked 
with HOP and p53 
 
Residues of 
Hsp90 alpha 
Residues of designed peptide 
Hydrophobic Hydrogen 
bonding 
Glu715 Asn2 - 
Met716 Ser3,Lys6 - 
Asp722 Lys - 
Met728 Ile1,Asn2,Tyr5 - 
Glu729 Arg11 - 
Glu730 Tyr9,Arg11,Gly12 Tyr5 
Val731 Gly12 Lys6 
Asp732 Ala10 - 
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Figure 15: 3D structure (wireframe) of the peptide inhibitor (INSAYKLKYARG) showing highest 
affinity colored according to groups. 
                                                                         
and the results analyzed. Results showed in Table 12 summarize all docking calculations, 
showing the differences of energy before and after inhibition. 
Table 13: Docking calculation between Hsp90 alpha, HOP and mutant p53 after Hsp90 alpha inhibition 
 
 
 
 
Complex Protein Energy 
Hsp90 alpha Mutant p53 -721.49 
Hsp90 alpha HOP -1179.80 
Hsp90alpha+INSAYKLKYARG Mutant p53 -606.49 
Hsp90alpha+INSAYKLKYARG HOP -626.56 
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Before inhibition the binding energy between Hsp90 alpha and mutant p53 was -721.49 and after 
inhibition it changed to -606.49, similarly the energy between Hsp90 alpha and HOP before 
inhibition was -1179.80 and after inhibition changed to -626.56. As it can be seen that the energy 
value changed to less negative this means that the complex is less stable after inhibition. Thus 
the objective to design a peptide inhibitor disrupting the interaction between Hsp90 alpha and 
HOP has been achieved computationally. 
                     
4.8  Discussion 
 
3D structures for various domains of Hsp90 alpha and its co-chaperones have been resolved and 
provide unique and important target for creation of new anticancer drugs. It can also be a 
Starting structure for virtual screening for identification of new lead compounds and their 
optimization. Many leads and drugs have been discovered by structure based virtual screening 
techniques using the N terminal domain of Hsp90 alpha. N terminal domain is the widely studied 
domain. Very few works have been done using Hsp90 alpha C terminal domain which has been 
shown to have second ATP binding site and mediates in binding to co chaperone for proper 
chaperoning activity. In the present study C terminal domain of Hsp90 alpha was modelled using 
PHYRE Human wild type p53 - 2OCJ, mutant p53 -2QVQ, HOP - 1ELR, Hsp70-3ATU and 
Hsp40-2QLD were retrieved from protein data bank (PDB). The structures were minimized 
using UCSF CHIMERA. Protein-protein interaction study was performed with Hsp90 alpha and 
its co-chaperones Hsp70, Hsp40 and HOP along with client protein p53. Results showed that 
Hsp90 alpha binds strongly to HOP than other co-chaperones and complex formation is 
important for proper chaperoning activity of Hsp90 alpha as complex binds more strongly to 
client proteins than Hsp90 alpha. Peptides were designed to disrupt the interaction between 
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Hsp90 alpha and HOP.  Structures’ having minimum binding energy is reported to take less time 
to bind and binding is more efficient as compared to the structure having more binding energy. 
Hence the peptide having the minimum binding energy towards Hsp90 alpha was selected as the 
best antagonistic peptide against Hsp90 alpha. Since peptide may form aggregates their 
amyloidogenicity was also predicted using PEPFOLD and modification was done accordingly. 
Among the various screened peptides, INSAYKLKYARG (Figure 15) showed high specific 
binding activity to the Hsp90 alpha. The peptide solubility was predicted and showed good 
solubility. Inhibition studies showed that the peptide reduced the affinity of Hsp90 alpha towards 
HOP and mutant p53 
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5.1 Conclusions 
 
Experiments have shown that protein-protein interactions and protein –ligand interactions play a 
crucial role in biological functions. Same is also true for Hsp90 alpha. Hsp90 alpha does not 
work alone but a host of other co-chaperones are required for proper chaperoning activity. Hsp 
organizing protein (HOP) is one of the most important co-chaperones which bring Hsp70 and 
Hsp90 alpha together for proper presentation of client proteins. In silico protein-protein 
interaction studies showed that Hsp90 alpha has higher affinity for HOP than other co-
chaperones. Hsp90 alpha in the multi-chaperone complex interacts more favorably with client 
proteins than Hsp90 alpha alone. Based on the above findings, peptide inhibitor were designed 
for specifically inhibiting Hsp90 alpha and HOP interaction that disrupts the formation of super 
complex.  An important  problem with peptides are tendency to aggregate which was also 
predicted and subsequently peptides were modified keeping the helix structure constant by 
substituting with amino acids having highest propensity for helix. The results showed that the 
peptide sequence INSAYKLKYARG showed highest energy of -861.81kcal/mol.  
 
5.2 Future perspectives 
The work done so far and all the results obtained are based on promising and reliable softwares. 
The process of drug designing is very lengthy and an expensive process. In silico techniques has 
proved to be a very reliable technique for designing of new drug candidate and assessing their 
activity.  The in vitro and in vivo studies thus save a lot of initial cost. In this work, a new 
peptide (INSAYKLKYARG) was designed for disrupting the interaction of Hsp90 and HOP, so 
that the complex will not be formed necessary for chaperoning activity of Hsp90. The results 
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were solely based on docking calculations based on the fact that the more negative energy of 
interaction more stable is the interaction. Future work should be to study the whole system under 
molecular dynamics simulation so that the behavior in real systems can be assessed. After 
simulation in vitro and in vivo studies can be done. 
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